Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Liver cancer patients: which drug works best after immunotherapy?

NCT ID NCT06117891

Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This observational study follows 300 adults with advanced liver cancer that cannot be removed by surgery. All participants have already received a first-line immunotherapy combination (like atezolizumab plus bevacizumab). Researchers will collect data from routine care to see how well different second-line treatments work, focusing on how long patients live and how long their cancer is controlled. No extra visits or tests are required.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors choose the best second-line treatments for patients with advanced liver cancer after initial immunotherapy.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient differences and real-world variability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with a diagnosis of uHCC treated with first-line AB or another approved 1L-IO combo and in whom a decision to treat with a second-line of systemic therapy has been made by the treating physician. The investigator or a delegate at these centers collects historic data (demographic and clinical characteristics) from medical records if available. The investigator or a delegate collects treatment-related data during visits that take place in routine practice.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients, ≥ 18 years of age on the day of signing informed consent. * Confirmed diagnosis of uHCC, treated in a first-line setting with AB or another approved 1L-IO combo therapy. * Decision to initiate treatment with a second-line systemic treatment was made as per investigator's routine treatment practice prior to study enrollment. * Signed informed consent or (for patients under legal age) signed informed assent by the patient (where applicable) and signed informed consent by parents / legal guardian. * No participation in an investigational program with interventions outside of routine clinical practice. Exclusion Criteria: \- Not applicable

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Unresectable hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Unresectable hepatocellular carcinoma

Contacts and locations

Locations

  • Corporal Michael J Crescenz Department Of Veterans Affairs Medical Center

    Philadelphia, Pennsylvania, 19104, United States

  • Einstein Medical Center

    Philadelphia, Pennsylvania, 19141, United States

  • Many Locations

    Multiple Locations, Argentina

  • Many Locations

    Multiple Locations, Brazil

  • Many Locations

    Multiple Locations, China

  • Many Locations

    Multiple Locations, Colombia

  • Many Locations

    Multiple Locations, France

  • Many Locations

    Multiple Locations, Greece

  • Many Locations

    Multiple Locations, Italy

  • Many Locations

    Multiple Locations, South Korea

  • Many Locations

    Multiple Locations, Spain

  • Many Locations

    Multiple Locations, Taiwan

  • Many Locations

    Multiple Locations, Thailand

  • Mercy Medical Center - Medline Healthcare Services LLC

    Baltimore, Maryland, 21202, United States

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York, 14203, United States

  • University Of Cincinnati Division Of Hematology Oncology - UC Health System

    Cincinnati, Ohio, 45219, United States

  • University of Michigan Health System

    Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.